loader image
Sunday, December 22, 2024
73.6 F
McAllen
We Welcome your Press Release
- Advertisement -

Post-Exposure Prophylactic Use of Monoclonal Antibodies

Translate to Spanish or other 102 languages!

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.
The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – Monoclonal antibody infusion has been used quite extensively in treating mild-moderated SARS-CoV-2 infection. The primary objective of this treatment is to prevent the progression of disease to a severe stage requiring hospitalization. At DHR Health and DHR Health Institute for Research & Development, we have infused REGEN-COV monoclonal antibody to over 500 patients with mild-moderate SARS-CoV-2 infection with very satisfactory outcome. This included adults, children and pregnant women who were at high risk for developing severe COVID-19 disease.

“We are embarking on a new project that is both FDA and IRB-approved to infuse monoclonal antibodies to asymptomatic high-risk individuals who are COVID-19 negative but have been exposed to a COVID-19 positive patient” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The purpose of this initiative is to prevent the development of SARS-CoV-2 infection in qualified adults and children 12 years of age or over who are exposed to a COVID-19 positive patient for at least 15 minutes in a 24-hour period”.

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. To learn more about who would qualify for this treatment, please visit this website:https://dhrresearch.org/wp-content/uploads/2021/08/CHECKLIST-08-08-2021-1.pdf  or call the post-exposure prophylaxis hotline (956) 362-2357 (9:00 a.m. – 5:00 p.m.; M-F) for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

The Dangers of High Cholesterol, Dec. 29th

Mega Doctor News In recent years, there’s been a slight decline in...

Texas WIC Celebrates 50 Years of Service

Mega Doctor News AUSTIN – The Special Supplemental Nutrition Program for Women, Infants...

Moderna Pauses mRNA RSV Vaccine Trial For Children

Mega Doctor News By Jon Cohen / Science.org Recently approved adult vaccines against respiratory syncytial...

STHS Stroke Survivors Support Group Celebrates Five Years

Mega Doctor News A stroke is a life-changing incident that can leave a person...
- Advertisement -
×